Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477197 | 0.89 | KDM4E (0.52) | KMT2AALDH1A1KDM4ETSHRTP53 | |
| SCHEMBL5013 | 0.89 | KDM4E (0.52) | KMT2AALDH1A1KDM4ETSHRTP53 | |
| Hydrochloric Acid SCHEMBL311054 | 0.86 | KDM4E (0.50) | KMT2AALDH1A1KDM4ETP53MAPT | |
| Piperazine SCHEMBL28080505 | 0.86 | KDM4E (0.50) | KMT2AALDH1A1KDM4ETSHRTP53 | |
| Potassium SCHEMBL30601760 | 0.86 | KDM4E (0.50) | KMT2AALDH1A1KDM4ETSHRTP53 | |
| SCHEMBL8742086 | 0.86 | KDM4E (0.50) | KMT2AALDH1A1KDM4ETSHRTP53 | |
| Trifluoroacetic Acid SCHEMBL5402957 | 0.84 | PKM (0.40) | KMT2AALDH1A1KDM4ETSHRTP53 | |
| Methylene Chloride SCHEMBL16447276 | 0.80 | KDM4E (0.45) | KMT2AALDH1A1KDM4ETSHRTP53 | |
| SCHEMBL92545 | 0.80 | KDM4E (0.56) | KMT2AALDH1A1KDM4ETSHRTP53 | |
| Piperidine SCHEMBL28145582 | 0.80 | KDM4E (0.56) | KMT2AALDH1A1KDM4ETSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1496982-A4 | SOLID FORMS OF SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2006-07-19 | — | — | EP | disclosed |
| US-6960590-B2 | Orally active salts with tyrosine kinase activity | MERCK & CO. INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1328519-B1 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2005-09-07 | — | — | EP | disclosed |
| CN-1213045-C | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20050113577-A1 | Solid forms of slats with tyrosine kinase activity | KARKI SHYAM B (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050096344-A1 | Tyrosine kinase inhibitors | FRALEY MARK E (US) | 2005-05-05 | — | — | US | disclosed |
| EP-1226136-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1328519-A4 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1496982-A2 | SOLID FORMS OF SALTS WITH TYROSINE KINASE ACTIVITY | Merck & Co., Inc. (US) | 2003-10-30 | — | — | EP | disclosed |
| WO-2003088900-A2 | SOLID FORMS OF SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO., INC. (US) | 2003-10-30 | — | — | WO | disclosed |
| EP-1328519-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | Merck & Co., Inc. (US) | 2003-07-23 | — | — | EP | disclosed |
| CN-1409708-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2003-04-09 | — | — | CN | disclosed |
| WO-2003020699-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | disclosed |
| EP-1226136-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | MERCK & CO., INC. | 2002-06-13 | — | — | US | disclosed |
| WO-2002032861-A2 | ORALLY ACTIVE SALTS WITH TYROSINE KINASE ACTIVITY | MERCK & CO., INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| US-6306874-B1 | ENZYME INHIBITORS SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, AND THE LIKE IN MAMMALS. | MERCK & CO., INC. | 2001-10-23 | — | — | US | disclosed |
| WO-2001029025-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072526-A1 | Orally active salts with tyrosine kinase activity | TEK, FLT1, TIE1 | KMT2A 3329/4885ALDH1A1 2584/4885KDM4E 3140/4885 |
| US-20050096344-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KMT2A 3298/4885ALDH1A1 3104/4885KDM4E 2200/4885 |
| US-20050113577-A1 | Solid forms of slats with tyrosine kinase activity | ROS1, MERTK, LYN | KMT2A 776/4885ALDH1A1 1704/4885KDM4E 1070/4885 |
| US-20080274107-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KMT2A 3298/4885ALDH1A1 3104/4885KDM4E 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.